Dr. Schwartzberg has disclosed that he receives consulting fees and/or honoraria from Amgen Inc., Genentech, Inc., and TESARO, Inc.; is a scientific advisor for Bristol-Myers Squibb Company, Caris Life Sciences, and Helsinn; and is on the product/speakers bureau for Genentech, Inc. and Pfizer Inc. Dr. Blair has disclosed that she has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
JatoiIChenBEAndersonWFRosenbergPS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol2007;25:1683–1690.
WeissANoorbakhshATokinC. Hormone receptor-negative breast cancer: undertreatment of patients over 80. Ann Surg Oncol2013;20:3274–3278.
KimickGGMussHB. Breast disease. In: HalterJBOuslanderJGTinettiME eds. Hazzard's Geriatric Medicine and Gerontology. Columbus, OH: McGraw Hill; 2009.
JoergerMThurlimannBSavidanA. Treatment of breast cancer in the elderly: a prospective population-based Swiss Study. J Geriatr Oncol2013;4:39–47.
AngaritaFAChesneyTElserC. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol2015;41:625–634.
CortadellasTGascónACórdobaO. Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer. Int J Surg2013;11:554–557.
HughesKSSchnaperLABellonJR. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol2013;31:2382–2387.
DinanMAMiXReedSD. Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005–2009. JAMA Oncol2015;1:158–166.
ShakSPetkovVIMillerDP. Breast cancer specific survival in 38,568 patients with node-negative hormone receptor-positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database [abstract]. Cancer Res2016;76(4 Suppl):Abstract P5-15-01.
Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet2015;386:1341–1352.
HussHBTuDIngleJN. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol2008;26:1956–1964.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)ColemanRPowlesT. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet2015;386:1353–1361.
TolaneySMBarryWTDangCT. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med2015;372:134–141.